annual cash & cash equivalents:
$4.87B-$1.73B(-26.23%)Summary
- As of today (August 20, 2025), GSK annual cash & cash equivalents is $4.87 billion, with the most recent change of -$1.73 billion (-26.23%) on December 31, 2024.
- During the last 3 years, GSK annual cash & cash equivalents has fallen by -$998.45 million (-17.00%).
- GSK annual cash & cash equivalents is now -56.53% below its all-time high of $11.21 billion, reached on December 31, 2009.
Performance
GSK Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$4.96B-$829.72M(-14.33%)Summary
- As of today (August 20, 2025), GSK quarterly cash & cash equivalents is $4.96 billion, with the most recent change of -$829.72 million (-14.33%) on June 30, 2025.
- Over the past year, GSK quarterly cash & cash equivalents has increased by +$1.19 billion (+31.52%).
- GSK quarterly cash & cash equivalents is now -68.08% below its all-time high of $15.54 billion, reached on March 31, 2015.
Performance
GSK quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
GSK Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -26.2% | +31.5% |
| 3 y3 years | -17.0% | -37.5% |
| 5 y5 years | -23.1% | -51.4% |
GSK Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -48.6% | at low | -47.7% | +31.5% |
| 5 y | 5-year | -48.6% | at low | -52.2% | +31.5% |
| alltime | all time | -56.5% | >+9999.0% | -68.1% | >+9999.0% |
GSK Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $4.96B(-14.3%) |
| Mar 2025 | - | $5.79B(+18.8%) |
| Dec 2024 | $4.87B(-26.2%) | $4.87B(+13.1%) |
| Sep 2024 | - | $4.31B(+14.3%) |
| Jun 2024 | - | $3.77B(-27.1%) |
| Mar 2024 | - | $5.17B(-21.7%) |
| Dec 2023 | $6.61B(-30.3%) | $6.61B(-19.0%) |
| Sep 2023 | - | $8.16B(-1.4%) |
| Jun 2023 | - | $8.27B(-4.1%) |
| Mar 2023 | - | $8.62B(-9.0%) |
| Dec 2022 | $9.48B(+61.4%) | $9.48B(+18.5%) |
| Sep 2022 | - | $7.99B(+0.8%) |
| Jun 2022 | - | $7.93B(-23.5%) |
| Mar 2022 | - | $10.37B(+76.6%) |
| Dec 2021 | $5.87B(-32.6%) | $5.87B(+23.9%) |
| Sep 2021 | - | $4.74B(-3.7%) |
| Jun 2021 | - | $4.92B(-26.0%) |
| Mar 2021 | - | $6.65B(-23.7%) |
| Dec 2020 | $8.71B(+37.3%) | $8.71B(+54.3%) |
| Sep 2020 | - | $5.64B(-44.6%) |
| Jun 2020 | - | $10.20B(+69.4%) |
| Mar 2020 | - | $6.02B(-5.1%) |
| Dec 2019 | $6.34B(+25.8%) | $6.34B(+17.2%) |
| Sep 2019 | - | $5.41B(+1.1%) |
| Jun 2019 | - | $5.35B(-2.5%) |
| Mar 2019 | - | $5.49B(+8.9%) |
| Dec 2018 | $5.04B(-6.3%) | $5.04B(-1.6%) |
| Sep 2018 | - | $5.12B(-7.9%) |
| Jun 2018 | - | $5.56B(-6.3%) |
| Mar 2018 | - | $5.94B(+10.3%) |
| Dec 2017 | $5.38B(-15.3%) | $5.38B(-19.6%) |
| Sep 2017 | - | $6.69B(+24.6%) |
| Jun 2017 | - | $5.37B(-9.0%) |
| Mar 2017 | - | $5.90B(-7.1%) |
| Dec 2016 | $6.35B(-28.5%) | $6.35B(+0.8%) |
| Sep 2016 | - | $6.30B(-10.5%) |
| Jun 2016 | - | $7.05B(+6.0%) |
| Mar 2016 | - | $6.65B(-25.2%) |
| Dec 2015 | $8.89B(+25.2%) | $8.89B(-3.8%) |
| Sep 2015 | - | $9.24B(-23.8%) |
| Jun 2015 | - | $12.12B(-22.0%) |
| Mar 2015 | - | $15.54B(+118.8%) |
| Dec 2014 | $7.10B(-25.5%) | $7.10B(-0.1%) |
| Sep 2014 | - | $7.11B(+25.2%) |
| Jun 2014 | - | $5.68B(-7.1%) |
| Mar 2014 | - | $6.11B(-35.9%) |
| Dec 2013 | $9.53B(+35.9%) | $9.53B(+69.4%) |
| Sep 2013 | - | $5.63B(+20.9%) |
| Jun 2013 | - | $4.65B(-33.6%) |
| Dec 2012 | $7.01B(-24.4%) | $7.01B(+17.6%) |
| Sep 2012 | - | $5.96B(-50.3%) |
| Jun 2012 | - | $11.98B(+26.8%) |
| Mar 2012 | - | $9.45B(+6.6%) |
| Dec 2011 | $9.27B | - |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2011 | - | $8.86B(-10.0%) |
| Jun 2011 | - | $9.85B(-9.0%) |
| Mar 2011 | - | $10.82B(+3.1%) |
| Dec 2010 | $9.92B(-11.5%) | - |
| Sep 2010 | - | $10.49B(+1.2%) |
| Jun 2010 | - | $10.37B(-6.4%) |
| Mar 2010 | - | $11.08B(-1.4%) |
| Dec 2009 | $11.21B(+13.5%) | - |
| Sep 2009 | - | $11.24B(+15.3%) |
| Jun 2009 | - | $9.75B(-0.6%) |
| Mar 2009 | - | $9.81B(-6.7%) |
| Dec 2008 | $9.88B(-0.9%) | - |
| Sep 2008 | - | $10.51B(-7.5%) |
| Jun 2008 | - | $11.36B(+48.3%) |
| Mar 2008 | - | $7.66B(+13.3%) |
| Dec 2007 | $9.97B(+67.5%) | - |
| Dec 2006 | $5.95B(-33.8%) | - |
| Dec 2005 | $8.99B(+17.6%) | - |
| Dec 2004 | $7.64B(+17.9%) | - |
| Sep 2004 | - | $6.76B(+23.2%) |
| Mar 2004 | - | $5.49B(+219.4%) |
| Dec 2003 | $6.48B(+63.0%) | $1.72B(-38.1%) |
| Sep 2003 | - | $2.78B(+4.5%) |
| Jun 2003 | - | $2.66B(+86.5%) |
| Mar 2003 | - | $1.42B(-16.0%) |
| Dec 2002 | $3.97B(+26.7%) | $1.70B(+29.1%) |
| Sep 2002 | - | $1.31B(-23.7%) |
| Jun 2002 | - | $1.72B(+29.4%) |
| Mar 2002 | - | $1.33B(+28.0%) |
| Dec 2001 | - | $1.04B(-40.2%) |
| Sep 2001 | - | $1.74B(+32.2%) |
| Jun 2001 | - | $1.31B(-46.7%) |
| Mar 2001 | - | $2.47B(+29.0%) |
| Dec 2000 | - | $1.91B(+170.2%) |
| Sep 2000 | - | $708.02M(-4.8%) |
| Jun 2000 | - | $743.56M(-18.0%) |
| Mar 2000 | - | $906.62M(+158.6%) |
| Dec 1999 | - | $350.65M(-15.0%) |
| Jun 1999 | - | $412.65M(+4.0%) |
| Dec 1998 | $3.14B(+14.7%) | $396.94M(+11.3%) |
| Jun 1998 | - | $356.77M(+0.2%) |
| Dec 1997 | $2.73B(+26.6%) | $356.06M(-19.7%) |
| Dec 1996 | $2.16B(+182.1%) | $443.57M(+270.3%) |
| Dec 1995 | $765.43M(+313.3%) | - |
| Jun 1995 | - | $119.79M(+41.4%) |
| Jun 1994 | $185.22M(-13.4%) | $84.73M(-10.9%) |
| Jun 1993 | $213.93M(+37.1%) | $95.05M(+108.4%) |
| Jun 1992 | $156.04M(+182.9%) | $45.60M(-17.3%) |
| Jun 1991 | $55.16M(-88.1%) | $55.16M(-88.1%) |
| Jun 1990 | $463.64M(-48.0%) | $463.64M(-48.0%) |
| Jun 1989 | $891.14M(+1203.7%) | $891.14M(+1203.7%) |
| Jun 1988 | $68.35M(+84.6%) | $68.35M(+84.6%) |
| Jun 1987 | $37.03M(-30.9%) | $37.03M(-30.9%) |
| Jun 1986 | $53.57M | $53.57M |
FAQ
- What is GSK plc annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for GSK plc?
- What is GSK plc annual cash & cash equivalents year-on-year change?
- What is GSK plc quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for GSK plc?
- What is GSK plc quarterly cash & cash equivalents year-on-year change?
What is GSK plc annual cash & cash equivalents?
The current annual cash & cash equivalents of GSK is $4.87B
What is the all time high annual cash & cash equivalents for GSK plc?
GSK plc all-time high annual cash & cash equivalents is $11.21B
What is GSK plc annual cash & cash equivalents year-on-year change?
Over the past year, GSK annual cash & cash equivalents has changed by -$1.73B (-26.23%)
What is GSK plc quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of GSK is $4.96B
What is the all time high quarterly cash & cash equivalents for GSK plc?
GSK plc all-time high quarterly cash & cash equivalents is $15.54B
What is GSK plc quarterly cash & cash equivalents year-on-year change?
Over the past year, GSK quarterly cash & cash equivalents has changed by +$1.19B (+31.52%)